



## Recent Advances in Ocular Drug Delivery

Guest Editors:

### Dr. Sven Schnichels

Centre for Ophthalmology,  
University Eye Hospital Tübingen,  
Tübingen, Germany

### Dr. Miguel González-Andrades

1. Maimonides Biomedical  
Research Institute of Cordoba  
(IMBIC), Department of  
Ophthalmology, Reina Sofia  
University Hospital and  
University of Cordoba, 14004  
Cordoba, Spain

2. Department of  
Ophthalmology, Massachusetts  
Eye and Ear and Schepens Eye  
Research Institute, Harvard  
Medical School, Boston, MA  
02114, USA

Deadline for manuscript  
submissions:

**closed (30 April 2022)**

### Message from the Guest Editors

Dear Colleagues,

Eye diseases are either treated with eye drops or, more rarely, systemically with intravitreal injections. However, the treatment efficacy of eye drops is low because only 1–5% of the administered drug remains in the eye long enough to be effective. For retinal diseases, this percentage drops down to less than 1% due to low ocular penetration. Therefore, repeated intravitreal injections are needed to treat retinal diseases, which can result in side effects and systemic spreading. Hence, more robust drug delivery systems need to be developed in order to avoid unwanted side effects and achieve better therapeutic outcomes. Nano- and microparticles offer great opportunities to overcome these challenges.

This Special Issue aims to capture the current state-of-the-art advances in ocular drug delivery. Suggested topics include the following: novel micro- and nanoparticles; improvements in implantable devices and slow release systems; new approaches in targeted ocular drug delivery; and challenges and obstacles of ocular drug delivery (systems).





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma